Logo image of ABSI

ABSCI CORP (ABSI) Stock Fundamental Analysis

USA - NASDAQ:ABSI - US00091E1091 - Common Stock

3.38 USD
-0.17 (-4.79%)
Last: 10/3/2025, 8:20:34 PM
3.45 USD
+0.07 (+2.07%)
After Hours: 10/3/2025, 8:20:34 PM
Fundamental Rating

3

Overall ABSI gets a fundamental rating of 3 out of 10. We evaluated ABSI against 536 industry peers in the Biotechnology industry. While ABSI seems to be doing ok healthwise, there are quite some concerns on its profitability. ABSI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABSI had negative earnings in the past year.
ABSI had a negative operating cash flow in the past year.
In the past 5 years ABSI always reported negative net income.
In the past 5 years ABSI always reported negative operating cash flow.
ABSI Yearly Net Income VS EBIT VS OCF VS FCFABSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -53.98%, ABSI is in line with its industry, outperforming 47.20% of the companies in the same industry.
Looking at the Return On Equity, with a value of -65.35%, ABSI is in the better half of the industry, outperforming 60.07% of the companies in the same industry.
Industry RankSector Rank
ROA -53.98%
ROE -65.35%
ROIC N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ABSI Yearly ROA, ROE, ROICABSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ABSI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABSI Yearly Profit, Operating, Gross MarginsABSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ABSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABSI has been increased compared to 1 year ago.
ABSI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ABSI has been reduced compared to a year ago.
ABSI Yearly Shares OutstandingABSI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ABSI Yearly Total Debt VS Total AssetsABSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 3.74 indicates that ABSI is not in any danger for bankruptcy at the moment.
ABSI's Altman-Z score of 3.74 is fine compared to the rest of the industry. ABSI outperforms 72.57% of its industry peers.
ABSI has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, ABSI perfoms like the industry average, outperforming 49.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.74
ROIC/WACCN/A
WACC10.03%
ABSI Yearly LT Debt VS Equity VS FCFABSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.39 indicates that ABSI has no problem at all paying its short term obligations.
The Current ratio of ABSI (4.39) is comparable to the rest of the industry.
ABSI has a Quick Ratio of 4.39. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.39, ABSI perfoms like the industry average, outperforming 50.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.39
ABSI Yearly Current Assets VS Current LiabilitesABSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

ABSI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.64%.
Looking at the last year, ABSI shows a very strong growth in Revenue. The Revenue has grown by 27.48%.
ABSI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.09% yearly.
EPS 1Y (TTM)-0.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)27.48%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%-53.31%

3.2 Future

The Earnings Per Share is expected to grow by 12.64% on average over the next years. This is quite good.
ABSI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 72.68% yearly.
EPS Next Y6.99%
EPS Next 2Y13.45%
EPS Next 3Y16.91%
EPS Next 5Y12.64%
Revenue Next Year4.13%
Revenue Next 2Y124.55%
Revenue Next 3Y106.91%
Revenue Next 5Y72.68%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABSI Yearly Revenue VS EstimatesABSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ABSI Yearly EPS VS EstimatesABSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABSI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABSI Price Earnings VS Forward Price EarningsABSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABSI Per share dataABSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ABSI's earnings are expected to grow with 16.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.45%
EPS Next 3Y16.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABSI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABSCI CORP

NASDAQ:ABSI (10/3/2025, 8:20:34 PM)

After market: 3.45 +0.07 (+2.07%)

3.38

-0.17 (-4.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners60%
Inst Owner Change4.84%
Ins Owners6.22%
Ins Owner Change0.74%
Market Cap505.38M
Analysts82.86
Price Target8.29 (145.27%)
Short Float %24.47%
Short Ratio6.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.25%
Min EPS beat(2)-10.99%
Max EPS beat(2)10.49%
EPS beat(4)1
Avg EPS beat(4)-4.09%
Min EPS beat(4)-13.12%
Max EPS beat(4)10.49%
EPS beat(8)1
Avg EPS beat(8)-4.03%
EPS beat(12)2
Avg EPS beat(12)-8.9%
EPS beat(16)2
Avg EPS beat(16)-13.12%
Revenue beat(2)0
Avg Revenue beat(2)-33.39%
Min Revenue beat(2)-54.7%
Max Revenue beat(2)-12.08%
Revenue beat(4)0
Avg Revenue beat(4)-33.74%
Min Revenue beat(4)-63.32%
Max Revenue beat(4)-4.87%
Revenue beat(8)0
Avg Revenue beat(8)-46.41%
Revenue beat(12)2
Avg Revenue beat(12)-35.35%
Revenue beat(16)2
Avg Revenue beat(16)-35.33%
PT rev (1m)0%
PT rev (3m)-10.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.37%
EPS NY rev (1m)-1.19%
EPS NY rev (3m)-1.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-69.44%
Revenue NY rev (1m)-2.06%
Revenue NY rev (3m)-22.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 122.13
P/FCF N/A
P/OCF N/A
P/B 2.91
P/tB 3.88
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.03
BVpS1.16
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.98%
ROE -65.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.52%
Cap/Sales 7.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.39
Altman-Z 3.74
F-Score4
WACC10.03%
ROIC/WACCN/A
Cap/Depr(3y)44.41%
Cap/Depr(5y)179.67%
Cap/Sales(3y)101.78%
Cap/Sales(5y)229.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y6.99%
EPS Next 2Y13.45%
EPS Next 3Y16.91%
EPS Next 5Y12.64%
Revenue 1Y (TTM)27.48%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%-53.31%
Revenue Next Year4.13%
Revenue Next 2Y124.55%
Revenue Next 3Y106.91%
Revenue Next 5Y72.68%
EBIT growth 1Y-18.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.04%
EBIT Next 3Y9.37%
EBIT Next 5YN/A
FCF growth 1Y7.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.72%
OCF growth 3YN/A
OCF growth 5YN/A